Search
×
FR

Placeholder headline

This is just a placeholder headline

API STD 521: Guide for Pressure-relieving and Depressuring Systems – Edition 6

$

682

BUY NOW

Placeholder headline

This is just a placeholder headline

API STD 653: Tank Inspection, Repair, Alteration, and Reconstruction – Edition 4

$

507

BUY NOW

Placeholder headline

This is just a placeholder headline

CSA Z662:19 – Oil and gas pipeline systems

$

1197

BUY NOW

Placeholder headline

This is just a placeholder headline

CSA Z341 Series-18: Storage of hydrocarbons in underground formations

$

878

BUY NOW

Placeholder headline

This is just a placeholder headline

CSA Z246.2-14 – Emergency preparedness and response for petroleum and natural gas industry systems

$

596

BUY NOW

Placeholder headline

This is just a placeholder headline

CSA Z341 Series:22 – Storage of hydrocarbons in underground formations

$

878

BUY NOW

Placeholder headline

This is just a placeholder headline

CSA Z731-09 (R2014) – Emergency Preparedness and Response

$

177

BUY NOW

Placeholder headline

This is just a placeholder headline

CSA Z662:23 – Oil and gas pipeline systems

$

1197

BUY NOW

Placeholder headline

This is just a placeholder headline

CSA Z341 Series:26 – Storage of Hydrocarbons in underground formations

$

878

BUY NOW

Placeholder headline

This is just a placeholder headline

CSA B51:24 Boiler, Pressure Vessel, and Pressure Piping Code

$

389

BUY NOW

ISO 22679:2021

ISO 22679:2021 Cardiovascular implants – Transcatheter cardiac occluders

CDN $379.00

SKU: 3aa04402b6f7 Category:

Description

This document specifies important in vitro tests including functional and durability characteristics of transcatheter cardiac occluders, and their delivery systems and accessories. This document does not specify exact test methods for functional and durability testing, but it offers requirements and recommendations for performance tests of the cardiac occluder system.

Surgical occluders have been omitted from the scope of this document given their significant differences in device geometry, materials, implantation methods, and test methods as compared to transcatheter cardiac occluders.

This document is applicable to all intracardiac occluders intended for transcatheter implantation in humans (e.g. atrial septal occluder, ventricular septal occluder, patent foramen ovale occluder, left atrial appendage occluder, and paravalvular leak occluders). This document does not cover non-cardiac occluders, but elements of this document can be applicable to patent ductus arteriosus occluders.

The following devices and components are outside the scope of this document: surgical devices, cardiac shunt devices, atrial flow regulators, active components (such as sensors), or degradable or animal tissue components.

This document is applicable to both newly developed and modified cardiac occluders, their accessory devices, packaging, and labelling.

This document defines operational conditions and performance requirements for cardiac occluders where either adequate scientific or clinical evidence, or both, exists for their justification.

NOTE      At the time of this document, it is impossible to take all future and emerging technologies into consideration. The cardiac occluder systems based on these new technologies can benefit from evaluation based on the basic requirements of this document. Testing beyond the scope of this document can also be necessary in order to verify and validate these cardiac occluder systems.

Edition

1

Published Date

2021-11-29

Status

PUBLISHED

Pages

72

Language Detail Icon

English

Format Secure Icon

Secure PDF

Abstract

This document specifies important in vitro tests including functional and durability characteristics of transcatheter cardiac occluders, and their delivery systems and accessories. This document does not specify exact test methods for functional and durability testing, but it offers requirements and recommendations for performance tests of the cardiac occluder system.

Surgical occluders have been omitted from the scope of this document given their significant differences in device geometry, materials, implantation methods, and test methods as compared to transcatheter cardiac occluders.

This document is applicable to all intracardiac occluders intended for transcatheter implantation in humans (e.g. atrial septal occluder, ventricular septal occluder, patent foramen ovale occluder, left atrial appendage occluder, and paravalvular leak occluders). This document does not cover non-cardiac occluders, but elements of this document can be applicable to patent ductus arteriosus occluders.

The following devices and components are outside the scope of this document: surgical devices, cardiac shunt devices, atrial flow regulators, active components (such as sensors), or degradable or animal tissue components.

This document is applicable to both newly developed and modified cardiac occluders, their accessory devices, packaging, and labelling.

This document defines operational conditions and performance requirements for cardiac occluders where either adequate scientific or clinical evidence, or both, exists for their justification.

NOTE      At the time of this document, it is impossible to take all future and emerging technologies into consideration. The cardiac occluder systems based on these new technologies can benefit from evaluation based on the basic requirements of this document. Testing beyond the scope of this document can also be necessary in order to verify and validate these cardiac occluder systems.

Previous Editions

Can’t find what you are looking for?

Please contact us at: